However, the fact that we found a nearly similar expression of IL-6 in both groups (a high ∆CT value indicates low expression of the gene (↑∆CT = ↓expression) may be linked to the usage of natalizumab as a therapeutic for MS. Here, IL6 is linked to myeloid sarcoma.